DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Heart failure (HF) continues to be a major global health problem with a notable impact in terms of morbidity and mortality and so, in consequence, with a large unmet necessity for new therapies. The inhibition of sodium-glucose cotransporter 2 (SGLT2) causes glycosuria and natriuresis, leading to re...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
BioExcel Publishing Ltd,
2020-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|